28例吉非替尼—线治疗老年非小细胞肺癌的临床经验  

Clinical Study of Gefitinib as First-Line Therapy in Elderly Patients with Non-Small Cell Lung Cancer

作　　者：尤长宣[1] 苏瑾[1] 李金瀚[1] 盛信秀[1] 崔斐[1] 罗荣城[1] 

机构地区：[1]南方医科大学南方医院肿瘤中心,广州市510515

出　　处：《中国肿瘤临床》2010年第11期640-642,共3页Chinese Journal of Clinical Oncology

摘　　要：目的:探讨吉非替尼一线治疗晚期老年非小细胞肺癌(NSCLC)的疗效和安全性。方法:分析2005年6月～2008年9月在南方医院肿瘤中心接受吉非替尼(250mg/d)做为一线治疗的老年晚期NSCLC患者28例,主要分析中位生存期(OS)、无进展生存期(PFS)、客观有效率及毒副反应。结果:全组客观有效率:无CR,PR 10例(35.7%),SD 14例(50.0%)。中位PFS为6.5个月(95%CI 3.9～9.0个月),1年生存率为57.1%(16例),中位OS为12.8个月(95%CI 6.3～19.3个月)。毒副反应较轻,大多为1～2级,3级皮疹2例,3级腹泻1例,经对症治疗后症状缓解,不影响治疗。结论:吉非替尼一线治疗老年非小细胞肺癌具有较好的疗效,且耐受性良好。Objective： To investigate the efficacy and toxicity of Gefitinib as the first-line therapy in elderly patients with non-small cell lung cancer （NSCLC）. Methods： Clinical data of 28 elderly patients with advanced NSCLC administered oral Gefitinib （250 mg/d） as first-line therapy, who were admitted to our hospital during the period from June 2005 to September 2008, were analyzed. The focus point in the study included the median overall survival （OS）, progression-free survival （PFS）, response rate and toxicity. Results： No complete regression （CR） was seen in our cases. Partial response （PR） and stable disease （SD） were respectively found in 10 （35.7%） and 14 （50.0%） patients. The median PFS was 6.5 months （95% CI, 3.9-9.0 m） and OS was 12.8 months （95% CI, 6.3-19.3 m） in all the patients. The 1-year survival rate was achieved by 53.6% （16/28）. Adverse reactions were mild and reversible, and most reactions were at grade Ⅰ to Ⅱ. Grade-Ⅲ rash and diarrhea were respectively seen in 2 and 1 patients, with relief after symptomatic treatment. Conclusion： Our study suggests that Gefitinib as the first line therapy in the elderly non-small cell lung cancer patients has satisfactory curative effects, with a better drug tolerance.

关 键 词：非小细胞肺癌 吉非替尼 一线治疗 老年 

分 类 号：R734.2[医药卫生—肿瘤]